An overview of mouse models of hepatocellular carcinoma
- PMID: 37670307
- PMCID: PMC10481604
- DOI: 10.1186/s13027-023-00524-9
An overview of mouse models of hepatocellular carcinoma
Abstract
Hepatocellular carcinoma (HCC) has become a severe burden on global health due to its high morbidity and mortality rates. However, effective treatments for HCC are limited. The lack of suitable preclinical models may contribute to a major failure of drug development for HCC. Here, we overview several well-established mouse models of HCC, including genetically engineered mice, chemically-induced models, implantation models, and humanized mice. Immunotherapy studies of HCC have been a hot topic. Therefore, we will introduce the application of mouse models of HCC in immunotherapy. This is followed by a discussion of some other models of HCC-related liver diseases, including non-alcoholic fatty liver disease (NAFLD), hepatitis B and C virus infection, and liver fibrosis and cirrhosis. Together these provide researchers with a current overview of the mouse models of HCC and assist in the application of appropriate models for their research.
Keywords: Animal model; Hepatocellular carcinoma; Immunotherapy.
© 2023. BioMed Central Ltd., part of Springer Nature.
Conflict of interest statement
The authors declare no competing interests.
The authors declare no potential conflicts of interest.
Figures
Similar articles
-
Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research.Nat Rev Gastroenterol Hepatol. 2018 Sep;15(9):536-554. doi: 10.1038/s41575-018-0033-6. Nat Rev Gastroenterol Hepatol. 2018. PMID: 29904153 Review.
-
Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):179-187. doi: 10.1080/17474124.2019.1549989. Epub 2018 Dec 29. Expert Rev Gastroenterol Hepatol. 2019. PMID: 30791782 Review.
-
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.Front Endocrinol (Lausanne). 2023 Jun 8;14:1148934. doi: 10.3389/fendo.2023.1148934. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37361533 Free PMC article. Review.
-
Hepatocellular carcinoma and other complications of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A structured review of published works.Hepatol Res. 2021 Jan;51(1):19-30. doi: 10.1111/hepr.13583. Epub 2020 Dec 9. Hepatol Res. 2021. PMID: 33091191 Review.
-
Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.Aliment Pharmacol Ther. 2017 Dec;46(11-12):1061-1069. doi: 10.1111/apt.14342. Epub 2017 Sep 28. Aliment Pharmacol Ther. 2017. PMID: 28960360
Cited by
-
Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges.Biomedicines. 2024 Jul 22;12(7):1624. doi: 10.3390/biomedicines12071624. Biomedicines. 2024. PMID: 39062197 Free PMC article. Review.
References
-
- International Agency for Research on Cancer, World Health Organization. Cancer today(https://gco.iarc.fr/today/home).
-
- Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Reviews Disease Primers. 2021;7(1):6. - PubMed
-
- Stepanova M, De Avila L, Afendy M, Younossi I, Pham H, Cable R, et al. Direct and indirect economic burden of chronic liver disease in the United States. Clin Gastroenterol Hepatol. 2017;15(5):759–66. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources